// Biotech and Pharma Therapeutics Biogen builds case for Spinraza successor with fresh data March 11, 2026 / Spinal Muscular Atrophy Treatment / Salanersen Clinical Trial / Neurofilament Light Chain Biomarker / SMA Drug Development / Neurodegenerative Disease Therapy Biogen...

// Biotech and Pharma Therapeutics Medtronic, GE HealthCare expand patient monitoring alliance March 4, 2026 / Patient Monitoring Integration / Medtronic GE HealthCare Partnership / Ambulatory Monitoring Technology / Clinical Data Integration / Healthcare Technology Platforms Medtronic and GE HealthCare...

// Biotech and Pharma Therapeutics Sarepta CEO Doug Ingram To Step Down as Muscular Dystrophy Mission Hits Home February 25, 2026 / Sarepta Therapeutics Leadership Change / Duchenne Muscular Dystrophy Gene Therapy / Elevidys FDA Approval / Myotonic Dystrophy DM1...

// Biotech and Pharma Therapeutics Ionis Paves Its Own Path as Initial Tryngolza Launch Defies Expectations February 18, 2026 / Ionis antisense therapy / Tryngolza hypertriglyceridemia / familial chylomicronemia syndrome / triglyceride lowering treatment / chronic hepatitis B functional cure...

// Biotech and Pharma Therapeutics Leica Biosystems revolutionizes histology workflows with global launch of the Leica CM1950 Cryostat with DualEcoTec Cooling System February 12, 2026 / Histology Workflow Innovation / Cryostat Technology / In Vitro Diagnostics / Sustainable Laboratory Equipment...

// Biotech and Pharma Therapeutics GSK delivers in new CEO Miels’ first financial update February 4, 2026 / gsk-earnings / hiv-respiratory-oncology / pipeline-expansion / new-ceo-miels / drug-approvals-2026 GSK reported strong 2025 financial results under new CEO Luke Miels, driven by...

// Biotech and Pharma Therapeutics Swiss Fire Aftermath Highlights Urgent Need For European Antimicrobial Incentives January 28, 2026 / burn-treatment / antimicrobial-resistance / EMA-approval / sulbactam-durlobactam / EU-drug-access A Swiss fire disaster underscores Europe’s urgent need for novel antimicrobials, as...

// Biotech and Pharma Therapeutics Employer Health Costs: Amid Continual Increases the Cost of Doing Nothing is Too High January 21, 2026 / healthcare-costs / employer-benefits / obesity-drugs / self-funded-insurance / chronic-disease-management Rising employer healthcare costs, driven by high-cost claims...

// Biotech and Pharma Therapeutics 5 topics to watch as MDUFA negotiations restart January 14, 2026 / MDUFA VI / FDA medical devices / user fee negotiations / medtech funding / healthcare regulation FDA and medtech industry negotiations for MDUFA...

// Biotech and Pharma Therapeutics Stanford Healthcare cuts EHR training time by half while increasing learning retention January 5, 2026 / EHR training efficiency / adaptive learning healthcare / clinical onboarding optimization / Stanford Healthcare informatics / electronic health record...